Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035

View original at globenewswire.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Generic/biosimilar ADCs are the fastest growing drug type segment

    80% confidence

  • Global antitumor ADC drugs market will grow from $8.33B in 2026 to $24.75B in 2035 at 12.86% CAGR

    80% confidence

  • Branded ADC drugs represent 75% market share in 2024

    80% confidence

  • Hematologic cancers represent 35% of ADC therapeutic area market in 2024

    80% confidence

  • Cytotoxic payloads represent 70% of ADC payload market share in 2024

    80% confidence

  • IV route accounts for 90% of ADC administration in 2024

    80% confidence

  • Hospital pharmacies and oncology centers represent 70% of ADC distribution in 2024

    80% confidence

  • North America holds 55% revenue share of ADC market in 2024

    80% confidence

  • Solid tumors represent the fastest growing therapeutic area for ADCs

    80% confidence

  • Cleavable linkers represent 60% of ADC linker market share in 2024

    80% confidence

  • Asia-Pacific is the fastest growing ADC market region

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 — Source | Via News | ViaNews Market